<DOC>
	<DOC>NCT00127829</DOC>
	<brief_summary>This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.</brief_summary>
	<brief_title>Study Evaluating Gefitinib (IRESSAÂ®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirmed solid tumor refractory to conventional treatment or whom no standard of treatment exists Life expectancy of &gt; 12 weeks World Health Organization (WHO) performance status of &lt; 2 Known severe hypersensitivity to gefitinib or any of the excipients of this product Less than 4 weeks since completion of prior chemotherapy or radiation therapy (except nitrosoureas or mitomycinC which must have a wash out period of 6 weeks) Incomplete healing from previous oncologic or other major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>